Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00219609 · ClinicalTrials.gov registry record · Phase 2
Assessment Of Safety Of UK-390,957
A Phase 2 study of Ejaculation, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,058
- Enrollment target
- 20
- Study locations
NCT00219609: Completed Phase 2 study of Ejaculation, sponsored by Pfizer.
NCT00219609 is a Phase 2 study of Ejaculation that has completed, run by Pfizer. The registered enrollment target is 1,058 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (695% higher). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00219609, a Phase 2 study of Ejaculation, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,058 participants
- Enrollment target
- 20
- Study locations
Study Summary
To determine whether UK-390,957 is a safe treatment for premature ejaculation.
Conditions Studied
Interventions
- DRUG UK-390,957
Study Locations (20)
California
- Pfizer Investigational Site - Anaheim
- Pfizer Investigational Site - Atherton
- Pfizer Investigational Site - Beverly Hills
- Pfizer Investigational Site - Laguna Woods
- Pfizer Investigational Site - Newport Beach
- Pfizer Investigational Site - Redwood City
- Pfizer Investigational Site - San Diego
- Pfizer Investigational Site - Tarzana
- Pfizer Investigational Site - Walnut Creek
Indiana
- Pfizer Investigational Site - Evansville
- Pfizer Investigational Site - Fort Wayne
- Pfizer Investigational Site - Indianapolis
Florida
- Pfizer Investigational Site - Aventura
- Pfizer Investigational Site - New Port Richey
Kentucky
- Pfizer Investigational Site - Lexington
- Pfizer Investigational Site - Madisonville
Arizona
- Pfizer Investigational Site - Tucson
Colorado
- Pfizer Investigational Site - Aurora
Connecticut
- Pfizer Investigational Site - Waterbury
Louisiana
- Pfizer Investigational Site - Metairie
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,058 participants |
| Start Date | 2005-01 |
| Est. Completion | 2006-03 |
| Phase | Phase 2 |
What the finished NCT00219609 record still lists
NCT00219609 is an interventional study that assigns participants to a tested intervention. Its 1,058 participants enrollment target places it among the larger protocols in the corpus, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (695% higher).
The record links to 1 condition, with Ejaculation appearing as the primary indexed condition, and to 1 intervention - of which UK-390,957 is the first listed.
NCT00219609 names 20 study sites across 8 states, led by California, Indiana, Florida.
Frequently Asked Questions
What is clinical trial NCT00219609 about?
NCT00219609 is a clinical study titled "Assessment Of Safety Of UK-390,957". To determine whether UK-390,957 is a safe treatment for premature ejaculation.
What is the current status of trial NCT00219609?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,058 participants. The study started on 2005-01. Estimated completion is 2006-03.
What conditions does trial NCT00219609 study?
This clinical trial studies the following conditions: Ejaculation.
What interventions are being tested in trial NCT00219609?
The interventions under investigation include: UK-390,957 (DRUG).
Who is sponsoring clinical trial NCT00219609?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00219609 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ejaculation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00219609's enrollment target sits among peer trials
1,058 24th of 2000 higher than 1,977 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03588286 · 1,058 participants · NA
Programmed Ventricular Stimulation to Risk Stratify for Early Cardioverter-Defibrillator (ICD) Implantation to Prevent Tachyarrhythmias Following Acute Myocardial Infarction (PROTECT-ICD)
- NCT05125302 · 1,059 participants · Phase 3
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
- NCT07018869 · 1,057 participants · Phase 3
Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors
- NCT05520762 · 1,060 participants · NA
Hospital Airway Resuscitation Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia